Literature DB >> 8942885

The efficacy of topical metronidazole in the treatment of ocular rosacea.

D A Barnhorst1, J A Foster, K C Chern, D M Meisler.   

Abstract

PURPOSE: The purpose of the study is to investigate the efficacy of metronidazole topical gel in the treatment of ocular rosacea.
METHODS: Ten patients with ocular rosacea were treated prospectively with lid hygiene and topical metronidazole applied to the lid margin in one eye and lid hygiene alone in the fellow eye. The treatment period was 12 weeks. A masked observer graded the ocular findings at the initial visit and at the conclusion of the treatment period. Pretreatment scores were compared with post-treatment scores with respect to ocular surface, eyelid margin, and combined eyelid plus ocular surface.
RESULTS: Eight of ten treated eyes improved, whereas only five of ten control eyes improved. There was a statistically significant improvement in the eyelid score in both the treated and control groups (P = 0.003, P = 0.025, respectively), but no significant improvement in the ocular surface score in either group. When the pretreatment and post-treatment eyelid and ocular surface scores were combined, there was a significant improvement in the treated eyes but not in the control eyes (P = 0.022, P = 0.10, respectively). No adverse effects of the metronidazole treatment were encountered in this study.
CONCLUSION: Metronidazole topical gel may be a safe and effective means of treating rosacea blepharitis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8942885     DOI: 10.1016/s0161-6420(96)30412-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  8 in total

Review 1.  Interventions for chronic blepharitis.

Authors:  Kristina Lindsley; Sueko Matsumura; Elham Hatef; Esen K Akpek
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 2.  The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction.

Authors:  Gerd Geerling; Joseph Tauber; Christophe Baudouin; Eiki Goto; Yukihiro Matsumoto; Terrence O'Brien; Maurizio Rolando; Kazuo Tsubota; Kelly K Nichols
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

Review 3.  Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment.

Authors:  Mark S Milner; Kenneth A Beckman; Jodi I Luchs; Quentin B Allen; Richard M Awdeh; John Berdahl; Thomas S Boland; Carlos Buznego; Joseph P Gira; Damien F Goldberg; David Goldman; Raj K Goyal; Mitchell A Jackson; James Katz; Terry Kim; Parag A Majmudar; Ranjan P Malhotra; Marguerite B McDonald; Rajesh K Rajpal; Tal Raviv; Sheri Rowen; Neda Shamie; Jonathan D Solomon; Karl Stonecipher; Shachar Tauber; William Trattler; Keith A Walter; George O Waring; Robert J Weinstock; William F Wiley; Elizabeth Yeu
Journal:  Curr Opin Ophthalmol       Date:  2017-01       Impact factor: 3.761

Review 4.  [Treatment options for chronic blepharitis considering current evidence].

Authors:  C Auw-Hädrich; T Reinhard
Journal:  Ophthalmologe       Date:  2016-12       Impact factor: 1.059

Review 5.  Interventions for rosacea.

Authors:  Esther J van Zuuren; Zbys Fedorowicz; Ben Carter; Mireille M D van der Linden; Lyn Charland
Journal:  Cochrane Database Syst Rev       Date:  2015-04-28

6.  Clinical Findings, Follow-up and Treatment Results in Patients with Ocular Rosacea.

Authors:  İlkay Kılıç Müftüoğlu; Yonca Aydın Akova
Journal:  Turk J Ophthalmol       Date:  2016-01-05

Review 7.  The Case for a More Holistic Approach to Dry Eye Disease: Is It Time to Move beyond Antibiotics?

Authors:  Azadeh Tavakoli; Judith Louise Flanagan
Journal:  Antibiotics (Basel)       Date:  2019-06-30

Review 8.  Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments.

Authors:  E J van Zuuren; Z Fedorowicz; J Tan; M M D van der Linden; B W M Arents; B Carter; L Charland
Journal:  Br J Dermatol       Date:  2019-03-10       Impact factor: 9.302

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.